Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. 8-K earnings release, 10-K stay in one workspace.
ANIK
$19.36
-1.53%
ANIK
· Anika Therapeutics, Inc.
$19.36
-0.30 (-1.53%)
At close · Oct 1
View the 10-Q filed Jul 29, 2026
Return incl. dividend (before tax)
Customer concentration
— top customer 53% of revenue
One customer — 53% of revenue (the three-months ended June 30, 2026)
“Revenue from the Company's sole significant customer, Johnson & Johnson MedTech ("J&J MedTech"), part of the Johnson & Johnson Medical Companies, as a percentage of the Company's total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”
One customer — 50% of revenue (the six-months ended June 30, 2026)
“Revenue from the Company's sole significant customer, Johnson & Johnson MedTech ("J&J MedTech"), part of the Johnson & Johnson Medical Companies, as a percentage of the Company's total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”
One customer — 50% of revenue (the six-months ended June 30, 2025)
“Revenue from the Company's sole significant customer, Johnson & Johnson MedTech ("J&J MedTech"), part of the Johnson & Johnson Medical Companies, as a percentage of the Company's total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”
One customer — 50% of revenue (the three-months ended June 30, 2025)
“Revenue from the Company's sole significant customer, Johnson & Johnson MedTech ("J&J MedTech"), part of the Johnson & Johnson Medical Companies, as a percentage of the Company's total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”
Market Cap
$267.26M
Shares
13.38M
Volume · Oct 1
111.91K
Avg daily vol (3M)
96.85K
All webcasts
Earnings call · FY2019 Q4
Anika Therapeutics, Inc. (ANIK) Q4 2019 Earnings Call
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Revenue
$29.77M
+10.4% YoY
Diluted EPS
$0.28
-48.1% YoY
Gross margin
70.9%
-3.1 pp YoY
Net income
$4.05M
-47.5% YoY
Research materials
Open the source you need; every reader stays inside this workspace.
SEC filing · Item 2.02
8-K earnings release
Filed Feb 20, 2020 · complete as-filed document
SEC periodic report
10-K report
Filed Mar 6, 2020 · complete as-filed document